ONTARGET investigators. Renal outcomes with telmisartan, ramipril or both in people at hight vascular risk (the ONTARGET study): a multicentre, randomised, dual-blind, controlled trial - Mann, J F; Schmieder, R E; McQueen, M (Lancet, 2008)
et al.